With a 240.6m register, 63m is about a 25% turnover since the offer...
There is little bit of 'conjecture' out there, and I am cautiously optimistic' that BMS may make a 'counter-offer' around April 9-12 (for UK conference), which is also the 'indicative timeframe' for the next round of 'trial results' being released, particularly for Merck and BMS...
Again, to considered probably as conjecture, I'd suggest the if BMS's next round of 'results' maintain, improve upon, or only marginally reduce, we may see an 'offer' from them, last round BMS's drugs improved from 11% to 57% from memory with CA21, Merck's improves by only ~100% when 'combo'd' with CA21...
I've hinted in previous posts (based on a bit of research and digging) that the 'turnover' since the offer 'may' be someone positioning themselves for a move, and some 'wringing out' for profit-takers...
